ACE-031 and Tamoxifen Interaction: Avoid | Peptide Database

ACE-031 as a research tool is typically produced as a recombinant Fc-fusion protein verified by SDS-PAGE, SEC-HPLC (≥95% monomer), and endotoxin testing (LAL ≤0.1 EU/mg per recombinant protein standards). Ligand binding verification (ELISA or surface plasmon resonance for activin A, myostatin, GDF-11) confirms expected Kd values (~0.1–1 nM for activin A, ~0.5–2 nM for myostatin). For immune assays, Fc region controls (human IgG1 Fc) are mandatory to separate immunological effects of the Fc region (Fcγ receptor binding on macrophages and NK cells) from ligand-capture effects. Assay conditions specifying exogenous ligand concentrations (activin A, myostatin) are essential for reproducibility, as ACE-031’s immune effects in the absence of added ligand depend entirely on endogenous autocrine/paracrine ligand levels which vary substantially between cell types and culture conditions.

ACE-031’s neutralisation of activin A has direct anti-resorptive consequences through the osteoblast RANKL-OPG axis. Activin A (via ActRIIA/ALK-4/Smad2/3) upregulates RANKL expression in osteoblasts and suppresses OPG secretion, shifting the RANKL:OPG ratio toward net osteoclastogenesis. ACE-031 (which traps activin A) restores the RANKL:OPG balance: osteoblast conditioned media from activin A-treated ± ACE-031 cultures applied to RAW264.7 or primary BMDM osteoclast precursors demonstrates dose-dependent TRAP+ multinucleated osteoclast reduction. RANKL:OPG molar ratio (ELISA, R&D Systems DY805 sRANKL and DY805B OPG) in conditioned media is the primary mechanistic readout; serum RANKL and OPG as translational in vivo biomarkers at weekly intervals in OVX ± ACE-031 cohorts. Direct osteoclast ActRIIB expression: primary osteoclast precursors (BMDM, M-CSF 25 ng/mL 3d) and mature osteoclasts (RANKL 50 ng/mL + M-CSF 7-10d) express ActRIIB (RT-PCR, anti-ActRIIB antibody, R&D AF339). Myostatin and activin A direct stimulation of mature TRAP+ osteoclasts (pit resorption area on bovine bone slices, Osteoassay surface, μm², SEM or Osteo Assay fluorescent) establishes an ActRIIB-direct osteoclast stimulation mechanism fully abrogated by ACE-031 pre-incubation. This direct osteoclast RANKL-independent resorption pathway represents an additional bone resorption mechanism uniquely addressed by ActRIIB decoy receptor approach versus other anti-resorptive strategies.